Allovir Net Income Applicable To Common Shares Over Time
| ALVR Stock | USD 0.57 0.01 1.79% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Allovir Performance and Allovir Correlation. Allovir |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allovir. If investors know Allovir will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allovir listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.90) | Return On Assets (0.37) | Return On Equity (0.80) |
The market value of Allovir is measured differently than its book value, which is the value of Allovir that is recorded on the company's balance sheet. Investors also form their own opinion of Allovir's value that differs from its market value or its book value, called intrinsic value, which is Allovir's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allovir's market value can be influenced by many factors that don't directly affect Allovir's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allovir's value and its price as these two are different measures arrived at by different means. Investors typically determine if Allovir is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allovir's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Applicable To Common Shares Analysis
Compare Allovir and related stocks such as Anebulo Pharmaceuticals, Mineralys Therapeutics,, and AN2 Therapeutics Net Income Applicable To Common Shares Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANEB | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (6.8 M) | (11.7 M) | (11.7 M) | (10.6 M) | (10 M) |
| MLYS | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (3.4 M) | (19.4 M) | (29.8 M) | (26.8 M) | (28.2 M) |
| ANTX | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (34.4 M) | (14.6 M) | (28.1 M) | (42.8 M) | (38.5 M) | (40.4 M) |
| AVTE | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (9.8 M) | (23 M) | (23 M) | (20.7 M) | (19.7 M) |
| ADAG | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (16.7 M) | (42.6 M) | (73.2 M) | (73.2 M) | (65.9 M) | (62.6 M) |
| STOK | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (12.5 M) | (32.3 M) | (52.2 M) | (85.8 M) | (101.1 M) | (91 M) | (86.4 M) |
| BDTX | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (8.9 M) | (35.3 M) | (67.3 M) | (125.6 M) | (91.2 M) | (82.1 M) | (86.2 M) |
| FDMT | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (11.2 M) | (9.6 M) | (49.3 M) | (56.7 M) | (71.3 M) | (107.5 M) | (96.7 M) | (91.9 M) |
| ACRV | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (16.2 M) | (31.2 M) | (28.1 M) | (29.5 M) |
| CGEM | (704.7 K) | (704.7 K) | (704.7 K) | (704.7 K) | (130.5 K) | (109.5 K) | (316.7 K) | (14.2 M) | (14.2 M) | (20.7 M) | (51.8 M) | (65.6 M) | 111.2 M | 127.9 M | 134.3 M |
| AGIO | (43.6 M) | (43.6 M) | (43.6 M) | (43.6 M) | (53.5 M) | (117.7 M) | (198.5 M) | (314.7 M) | (346 M) | (411.5 M) | (327.4 M) | 1.6 B | (231.8 M) | (266.6 M) | (253.2 M) |
| CRNX | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (9.2 M) | (27.1 M) | (50.4 M) | (73.8 M) | (107.6 M) | (163.9 M) | (147.5 M) | (140.1 M) |
| INBX | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (19.4 M) | (31.2 M) | (51.4 M) | (76.1 M) | (81.8 M) | (145.2 M) | (130.7 M) | (124.2 M) |
| MRUS | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (17.4 M) | (25.1 M) | (47.4 M) | (64.8 M) | (28.3 M) | (55.2 M) | (85.5 M) | (66.8 M) | (131.2 M) | (118.1 M) | (112.2 M) |
| LYEL | (130.5 M) | (130.5 M) | (130.5 M) | (130.5 M) | (130.5 M) | (130.5 M) | (130.5 M) | (130.5 M) | (130.5 M) | (130.5 M) | (208.1 M) | (250.2 M) | (183.1 M) | (164.8 M) | (173 M) |
| KRON | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (16.1 M) | (88.4 M) | (151.1 M) | (133.2 M) | (119.9 M) | (125.9 M) |
| ANAB | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | (5.4 M) | (4.3 M) | (30.1 M) | (61.7 M) | (97.3 M) | (19.9 M) | (57.8 M) | (128.7 M) | (115.9 M) | (110.1 M) |
Allovir and related stocks such as Anebulo Pharmaceuticals, Mineralys Therapeutics,, and AN2 Therapeutics Net Income Applicable To Common Shares description
The net income that remains after preferred dividends have been deducted, available to common shareholders.My Equities
My Current Equities and Potential Positions
| Allovir | ALVR |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 0.57
Additional Tools for Allovir Stock Analysis
When running Allovir's price analysis, check to measure Allovir's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allovir is operating at the current time. Most of Allovir's value examination focuses on studying past and present price action to predict the probability of Allovir's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allovir's price. Additionally, you may evaluate how the addition of Allovir to your portfolios can decrease your overall portfolio volatility.